Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:country |
gptkb:Australia
|
| gptkbp:founded |
1916
|
| gptkbp:founder |
gptkb:Government_of_India
|
| gptkbp:headquarters_location |
gptkb:Melbourne
|
| https://www.w3.org/2000/01/rdf-schema#label |
CSL Australia
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:keyPerson |
gptkb:Paul_Perreault
|
| gptkbp:notableProject |
COVID-19 vaccine production
|
| gptkbp:numberOfEmployees |
over 25,000 (CSL Limited, 2023)
|
| gptkbp:originalName |
gptkb:Commonwealth_Serum_Laboratories
|
| gptkbp:parentCompany |
gptkb:CSL_Limited
|
| gptkbp:products |
pharmaceuticals
vaccines blood plasma products |
| gptkbp:servesArea |
global
|
| gptkbp:stockExchange |
gptkb:ASX
|
| gptkbp:stockSymbol |
gptkb:CSL
|
| gptkbp:subsidiary |
gptkb:CSL_Limited
|
| gptkbp:website |
https://www.csl.com.au/
|
| gptkbp:bfsParent |
gptkb:Canada_Steamship_Lines
gptkb:CSL_Group |
| gptkbp:bfsLayer |
7
|